Virtual Incision Corp., a company founded by faculty members at the University of Nebraska-Lincoln and UNMC, has announced the successful first-in-human use of its miniaturized robotically assisted surgical device.
The device is designed for general surgery abdominal procedures, with an initial focus on colon resection, a procedure performed to treat patients with lower gastrointestinal diseases including diverticulitis, colon polyps that are too large to be removed endoscopically, pre-cancerous and cancerous lesions of the colon and inflammatory bowel disease.
“To the best of our knowledge, this is the first time an active miniaturized robot has performed complex surgical tasks with the robot inside a living human, which is a significant milestone in robotics and in surgery,” said Shane Farritor, Ph.D., a UNL professor of mechanical engineering who is Virtual Incision’s co-founder and chief technical officer.
The robotically assisted colon resection procedures were completed in Asunción, Paraguay, as part of the safety and feasibility trial for the technology. The surgeries were successful and the patients are recovering well, according to a news release from the company.
“Virtual Incision’s robotically assisted surgical device achieved proof-of-concept in highly complex abdominal procedures,” said head surgeon Dmitry Oleynikov, M.D., chief of minimally invasive surgery at UNMC and co-founder of Virtual Incision.
“Additionally, we verified that our extensive regimen of bench, animal, cadaver, biocompatibility, sterilization, electrical safety, software, human factors and other testing enabled the safe use of this innovative technology.”
Unlike today’s large, mainframe-like robots that reach into the body from outside the patient, Virtual Incision’s robot platform features a small, self-contained surgical device that is inserted through a single midline umbilical incision in the patient’s abdomen. Virtual Incision’s technology is designed to utilize existing tools and techniques familiar to surgeons, and does not require a dedicated operating room or specialized infrastructure.
Because of its much smaller size, the robot is expected to be significantly less expensive than existing robotic alternatives for laparoscopic surgery, Dr. Oleynikov said. Virtual Incision’s technology promises to enable a minimally invasive approach to surgeries performed today with a large open incision, he said.
The robotically assisted surgical device is an investigational device and is not commercially available. John Murphy, Virtual Incision’s CEO, said robotically assisted surgical devices are beneficial, but existing surgical robots have limitations that prevent pervasive use during certain surgeries, such as colon resection. The firm will build upon the positive completion of the feasibility study, as it works toward clearance for the system in the United States.